GPR55 and pancreatic neoplasm: Similarly, in pancreatic cancer, the GPR55 inhibitor (R,R’)−4’-methoxy-1-naphthylfenoterol (MNF) suppresses tumor proliferation and enhances sensitivity to chemotherapeutics such as doxorubicin and gemcitabine [44, 45].